Public Willingness to Participate in COVID-19 Vaccine Clinical Trials: A Study from Jordan

References

• Worldometer. COVID-19 coronavirus pandemic; 2020.
   Google Scholar
• Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity. 2020;52(5):737–741. doi:10.1016/j.immuni.2020.04.012
   PubMed Web of Science ®Google Scholar
• Atkeson A. What Will Be the Economic Impact of Covid-19 in the Us? Rough Estimates of Disease Scenarios. National Bureau of Economic Research; 2020:0898–2937.
   Google Scholar
• Layne SP, Hyman JM, Morens DM, Taubenberger JK. New Coronavirus Outbreak: Framing Questions for Pandemic Prevention. American Association for the Advancement of Science; 2020.
   Google Scholar
• Nussbaumer‐Streit B, Mayr V, Dobrescu AI, et al. Quarantine alone or in combination with other public health measures to control COVID‐19: a rapid review. Cochrane Database Syst Rev. 2020;4.
   Google Scholar
• Lyu W, Wehby GL. Community use of face masks and COVID-19: evidence from a natural experiment of state mandates in the US: study examines impact on COVID-19 growth rates associated with state government mandates requiring face mask use in public. Health Aff. 2020;39(8):1419–1425. doi:10.1377/hlthaff.2020.00818
   PubMed Web of Science ®Google Scholar
• Courtemanche C, Garuccio J, Le A, Pinkston J, Yelowitz A. Strong social distancing measures in the United States reduced the COVID-19 growth rate: study evaluates the impact of social distancing measures on the growth rate of confirmed COVID-19 cases across the United States. Health Aff. 2020;39(7):1237–1246. doi:10.1377/hlthaff.2020.00608
   PubMed Web of Science ®Google Scholar
• Lurie N, Saville M, Hatchett R, Halton J. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020;382(21):1969–1973.
   PubMed Web of Science ®Google Scholar
• Singh K, Mehta S. The clinical development process for a novel preventive vaccine: an overview. J Postgrad Med. 2016;62(1):4–11. doi:10.4103/0022-3859.173187
   PubMed Web of Science ®Google Scholar
• WHO. Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations. WHO Expert Committee on Biological Standardization Fifty-Second Report. Geneva: World Health Organization; 2004:035–101.
   Google Scholar
• DeRoo SS, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA. 2020.
   Web of Science ®Google Scholar
• Schmotzer GL. Barriers and facilitators to participation of minorities in clinical trials. Ethn Dis. 2012;22(2):226–230.
   PubMed Web of Science ®Google Scholar
• Detoc M, Bruel S, Frappe P, Tardy B, Botelho-Nevers E, Gagneux-Brunon A. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020;38(45):7002–7006. doi:10.1016/j.vaccine.2020.09.041
   PubMed Web of Science ®Google Scholar
• Dodd RH, Cvejic E, Bonner C, Pickles K, McCaffery KJ. Willingness to vaccinate against COVID-19 in Australia. Lancet Infect Dis. 2020. doi:10.1016/S1473-3099(20)30559-4
   PubMed Web of Science ®Google Scholar
• Jiang HDC, Wang Z, Wang L, et al. Exploration and application of a novel attempt to recruit participants in clinical trials of vaccines under the emergency. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(9):963–967.
   Google Scholar
• World Medical A. World medical association declaration of helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194. doi:10.1001/jama.2013.281053
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus disease (COVID-19) pandemic. World Health Organization. 2020.
   Google Scholar
• Menzella F, Biava M, Barbieri C, Livrieri F, Facciolongo N. Pharmacological treatment of COVID-19: lights and shadows. Drugs Context. 2020;9:1–11. doi:10.7573/dic.2020-4-6
   Google Scholar
• Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. 2020;324(10):1–10. doi:10.1001/jama.2020.15543
   Web of Science ®Google Scholar
• Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet. 2020;396(10249):479–488. doi:10.1016/S0140-6736(20)31605-6
   PubMed Web of Science ®Google Scholar
• Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a Phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467–478.
   PubMed Web of Science ®Google Scholar
• Lackland DT, Sims-Robinson C, Jones Buie JN, Voeks JH. Impact of COVID-19 on clinical research and inclusion of diverse populations. Ethn Dis. 2020;30(3):429–432. doi:10.18865/ed.30.3.429
   Web of Science ®Google Scholar
• Farrell R, Michie M, Pope R. Pregnant women in trials of covid-19: a critical time to consider ethical frameworks of inclusion in clinical trials. Ethics Hum Res. 2020;42(4):17–23. doi:10.1002/eahr.500060
   PubMedGoogle Scholar
• AlNaamani K, AlSinani S, Barkun AN. Medical research during the COVID-19 pandemic. World J Clin Cases. 2020;8(15):3156–3163. doi:10.12998/wjcc.v8.i15.3156
   Web of Science ®Google Scholar
• Calina D, Hartung T, Docea AO, et al. COVID-19 vaccines: ethical framework concerning human challenge studies. Daru. 2020;1–6.
   Web of Science ®Google Scholar
• Eyal N, Lipsitch M, Smith PG. Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis. 2020;221(11):1752–1756. doi:10.1093/infdis/jiaa152
   PubMed Web of Science ®Google Scholar
• Grady C, Shah S, Miller F, et al. So much at stake: ethical tradeoffs in accelerating SARSCoV-2 vaccine development. Vaccine. 2020;38(41):6381–6387. doi:10.1016/j.vaccine.2020.08.017
   Web of Science ®Google Scholar
• Evans NG, Imperiale MJ. Human infection challenge studies: a test for the social value criterion of research ethics. mSphere. 2020;5(4):4. doi:10.1128/mSphere.00669-20
   Web of Science ®Google Scholar
• Francis A, Whittemore R, Jeffery DR, Pearce LB, Roth JA. Catecholamine-metabolizing enzyme activity in the nigrostriatal system. Biochem Pharmacol. 1987;36(13):2229–2231. doi:10.1016/0006-2952(87)90157-2
   Web of Science ®Google Scholar
• Keinonen T, Keränen T, Klaukka T, Saano V, Ylitalo P, Enlund H. Investigator barriers and preferences to conduct clinical drug trials in Finland: a qualitative study. Pharm World Sci. 2003;25(6):251–259. doi:10.1023/B:PHAR.0000006517.36241.a5
   Google Scholar
• Staniszewska A, Lubiejewska A, Czerw A, et al. Awareness and attitudes towards clinical trials among polish oncological patients who had never participated in a clinical trial. Adv Clin Exp Med. 2018;27(4):525–529. doi:10.17219/acem/68762
   Web of Science ®Google Scholar
• Hughson JA, Woodward-Kron R, Parker A, et al. A review of approaches to improve participation of culturally and linguistically diverse populations in clinical trials. Trials. 2016;17(1):263.
   PubMed Web of Science ®Google Scholar
• Friedman DB, Foster C, Bergeron CD, Tanner A, Kim SH. A qualitative study of recruitment barriers, motivators, and community-based strategies for increasing clinical trials participation among rural and urban populations. Am J Health Promot. 2015;29(5):332–338. doi:10.4278/ajhp.130514-QUAL-247
   PubMed Web of Science ®Google Scholar
• Bergeron CD, Foster C, Friedman DB, Tanner A, Kim SH. Clinical trial recruitment in rural South Carolina: a comparison of investigators’ perceptions and potential participant eligibility. Rural Remote Health. 2013;13(4):2567.
   PubMed Web of Science ®Google Scholar